South Africa Launches Game-Changing HIV Prevention Shot

South Africa just became one of the first countries to offer a groundbreaking HIV prevention injection that could change everything for the people most at risk.

The twice-yearly shot, called lenacapavir, arrived at Johannesburg's O.R. Tambo International Airport and is now undergoing final safety testing. By the end of May, it will be available for free at 360 public health clinics across the country.

Dr. Nonhlanhla Ndlovu, South Africa's newly appointed Deputy Director-General for HIV, AIDS, TB and sexually transmitted infections, is leading the charge. She's overseeing a program that will bring the injection directly to the people who need it most: adolescent girls and young women aged 15 to 24, who face the highest HIV risk in South Africa.

The injection is a game changer because it eliminates the daily pill burden. Clinical trials conducted in South Africa showed lenacapavir had near perfect effectiveness in preventing HIV infection.

Ndlovu's team has prepared youth-friendly services and youth zones inside clinics. They're partnering with universities and colleges to bring mobile clinics directly to campuses through Higher Health, the national agency serving students.

The rollout strategy reaches beyond clinic walls. SMS messaging will educate communities, while peer educators and youth ambassadors will connect young women to services. Schools will include information about lenacapavir in their curriculum, though the actual injections will happen at health facilities.

Ndlovu knows this work intimately. After graduating medical school in 1996, she treated TB and sexually transmitted infections in Durban. In 2003, she joined a pioneering project that rolled out HIV treatment in clinics before the government did, proving that specialized hospital care wasn't always necessary.

Why This Inspires

Dr. Ndlovu's journey from treating patients during the darkest days of the HIV epidemic to now leading the rollout of near-perfect prevention shows how far science and determination can take us. Her childhood dream of being a doctor, playing pretend while other kids played with dolls, evolved into a career fighting one of humanity's toughest health challenges.

South Africa is meeting weekly with manufacturer Gilead Sciences to ensure smooth distribution, while simultaneously pushing for local production that could make the injection available across Africa. Generic versions are expected in 2027 or 2028 at prices the government can afford.

For a country that's been at the heart of the HIV epidemic for decades, offering hope in a twice-yearly injection feels like the breakthrough everyone's been waiting for.